Détail du document
Identifiant
oai:HAL:hal-03851647v1
Sujet
glyco-engineering glycosides influenza viruses sialosides solid lipid microparticles [SDV.BIO]Life Sciences [q-bio]/Bio... [SDV.MHEP.MI]Life Sciences [q-bio]...Auteur
Richard, Emeline Traversier, Aurélien Julien, Thomas Rosa-Calatrava, Manuel Putaux, Jean-Luc Jeacomine, Isabelle Samain, EricLangue
enEditeur
HAL CCSD;Oxford University Press (OUP)
Catégorie
CNRS - Centre national de la recherche scientifique
Année
2022
Date de référencement
07/10/2023
Mots clés
solid lipid microparticles production sslms influenza virus sialylatedRésumé
International audience; Abstract Influenza viruses bind to their target through a multivalent interaction of their hemagglutinins (HAs) with sialosides at the host cell surface.
To fight the virus, one therapeutic approach consists in developing sialylated multivalent structures that can saturate the virus HAs and prevent the binding to host cells.
We describe herein the biotechnological production of sialylated solid lipid microparticles (SSLMs) in 3 steps: (i) a microbiological step leading to the large-scale production of sialylated maltodextrins by metabolic engineering of an Escherichia coli strain, (ii) a new in vitro glycosylation process using the amylomaltase MalQ, based on the transglycosylation of the terminal sialoside ligand of the sialylated maltodextrin onto a long-chain alkyl glucoside, and (iii) the formulation of the final SSLMs presenting a multivalent sialic acid.
We also describe the morphology and structure of the SSLMs and demonstrate their very promising properties as influenza virus inhibitors using hemagglutination inhibition and microneutralization assays on the human A/H1N1 pdm09 virus.
Richard, Emeline,Traversier, Aurélien,Julien, Thomas,Rosa-Calatrava, Manuel,Putaux, Jean-Luc,Jeacomine, Isabelle,Samain, Eric, 2022, Biotechnological production of sialylated solid lipid microparticles as inhibitors of influenza A virus infection, HAL CCSD;Oxford University Press (OUP)
